Important note: Information in this article was accurate in July 2002. The state of the art may have changed since the publication date.AIDSWEEKLY Plus; July 8, 2002
Michael Greer, Senior Medical Writer
Dr. Akhteruzzaman Molla and colleagues working at Abbott Laboratories' Global Pharmaceutical Research and Development organization in Abbott Park, Illinois evaluated the safety and efficacy of lopinavir in combination with a number of other protease inhibitors.
Lopinavir combines well with similar agents, enhancing viral suppression with limited toxicity, Molla and coauthors found.
Most of the protease inhibitors examined demonstrated additive effects when combined with lopinavir in vitro, they said. These agents included commonly used drugs such as indinavir and nelfinavir, as well as novel protease inhibitors like tipranavir and BMS-232632.
Lopinavir was particularly effective in combination with saquinavir, study data showed. The two agents displayed a synergistic relationship at all dose levels and ratios.
No lopinavir-induced cytotoxicity was seen at any of the concentrations tested (In vitro antiviral interaction of lopinavir with other protease inhibitors, Antimicrob Agents Chemother 2002 Jul;46(7):2249-53.
"These results suggest that administration of combinations of the appropriate dose of lopinavir with other protease inhibitors in vivo may result in enhanced antiviral activity with no associated increase in cellular cytotoxicity," Molla and colleagues concluded. "More importantly, the observed in vitro synergy between lopinavir and saquinavir provides a theoretical basis for the clinical exploration of a novel regimen of lopinavir-ritonavir and saquinavir."
The corresponding author for this report is Akhteruzzaman Molla, Department R47D, Building AP52N, Abbott Laboratories, 200 Abbott Park Rd., Abbott Park, IL 60064, USA. E-mail: akhter.m.molla@abbott.com.
A search at www.NewsRx.net using the term "AIDS and HIV therapy" yielded 1146 articles in 28 specialized reports.
Key points reported in this study include:
This article was prepared by AIDS Weekly editors from staff and other reports.
020708
AW020706
Copyright © 2002 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.